Taysha Gene Therapies (TSHA) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
1 of 2 scored quarters beat, yet the stock still fell after 1 of them (Nov 12, 2026). The market prices the whole print, not the headline beat. Chasing earnings pops is a coin flip.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 20268-K, before open · 7:30 am ET | −0.13 | −0.10 | +22.2% | $755,556.00 | $0.00 | −100.0% | −1.6%release day |
| Aug 11, 20268-K, after close · 4:05 pm ET | −0.11 | −0.13 | −13.5% | $618,182.00 | $0.00 | −100.0% | −4.1%next session |
| May 6, 20268-K, before open · 8:11 am ET | — | −0.12 | — | — | $0.00 | — | +0.6%release day |
| Nov 4, 20258-K, before open · 7:12 am ET | — | −0.09 | — | — | $0.00 | — | −4.3%release day |
| Aug 12, 20258-K, before open · 8:10 am ET | — | −0.09 | — | — | $2.0M | — | +5.4%release day |
| May 15, 20258-K, before open · 8:09 am ET | — | −0.08 | — | — | $2.3M | — | +8.0%release day |
| Feb 26, 20258-K, before open · 8:06 am ET | — | −0.07 | — | — | $2.0M | — | −4.7%release day |
| Nov 13, 20248-K, after close · 4:10 pm ET | — | −0.10 | — | — | $1.8M | — | +2.7%next session |
Estimate-vs-actual scoring began Jul 2026 and is still accruing: 2 of the 8 quarters above carry a scored estimate. We never backfill an estimate we didn't observe.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 3 | 3 | 6 | 6 |
| Avg estimate | −0.10 | −0.11 | −0.44 | −0.45 |
| Low estimate | −0.10 | −0.11 | −0.54 | −0.57 |
| High estimate | −0.10 | −0.11 | −0.40 | −0.33 |
| Year-ago EPS | — | −0.12 | −0.34 | −0.44E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 9 | 8 | 7 | 7 |
| Avg estimate | $2.0M | $685,714.00 | $1.6M | $19.5M |
| Low estimate | $2.0M | $685,714.00 | $863,817.00 | $10.3M |
| High estimate | $2.0M | $685,714.00 | $2.6M | $31.2M |
| Year-ago revenue | — | $0.00 | $9.8M | $1.6ME |
| Implied growth | — | — | −83.3% | +1089.8% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.10 | −0.11 | −0.44 | −0.45 |
| 7 days ago | −0.13 | — | −0.50 | −0.52 |
| 30 days ago | −0.13 | — | −0.50 | −0.52 |
| 60 days ago | −0.13 | — | −0.50 | −0.52 |
| 90 days ago | −0.12 | — | −0.46 | −0.46 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $−0.12 → $−0.10 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were Taysha Gene Therapies' latest quarterly earnings?
Taysha Gene Therapies reported diluted EPS of −0.10 and revenue of $0.00 on Nov 12, 2026.
How did Taysha Gene Therapies' stock move after its last earnings report?
Taysha Gene Therapies moved −1.6% in the session after its Nov 12, 2026 report.

